ClinicalTrials.gg
WithdrawnNCT04452474Updated Nov 8, 2021

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

A Phase 2/3 interventional study of Olokizumab 64 mg and Placebo in COVID-19, sponsored by R-Pharm. Withdrawn. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-11-08.

Sponsored by R-Pharm · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.

Read the detailed description
  1. Pilot phase: the first 100 patients will be randomized in two groups to receive OKZ or placebo (50 patients per group). Early futility analysis will be performed based on the results obtained in the pilot period after 100th patient completed Visit 29. Enrollment will be paused after randomization of 100th patient, then interim analysis will be performed when all 100 patients complete Visit Day 29 or discontinue the study.Based on results of the pilot phase analysis the study could be stopped.
  2. Pivotal phase: inclusion of patients until targeted sample size is reached and performing final safety and efficacy analysis.

Maximum expected study duration for each patient is 62 days, including 2 days of screening, 1 day of study drug administration, and 59 days of follow-up.

The study will include following periods:

  1. Screening period lasting up to 48 hours prior to Day 1. After signing the informed consent by the patient or the legally acceptable representative or when prior consent of the patient is not possible, and the subject's legally acceptable representative is not available, after obtaining documented approval/favorable opinion for individual cases by the Institutional Review Board / Independent Ethic Committee (IRB/IEC), investigator will assess the subject's eligibility for the study.
  2. Treatment period lasting from the beginning of Day 1 visit to 23:59 of the Day 1.

    Eligible patients will be randomized to one of two treatment groups to receive a single subcutaneous injection - OKZ 64 mg or placebo in addition to standard COVID-19 therapy according to institutional guidelines;

  3. Follow-up period lasting from 00:00 of the Day 2 to 23:59 of the Day 60. If the patient is discharged earlier than Day 15, at Days 15 and 29 5-point clinical status scale will be assessed at the study site visit or by phone interview. If the patient is discharged after Day 15, but earlier than Day 29, at Day 29 5-point clinical status scale will be assessed at the study site visit or by phone interview. The end of study is Day 60, when 5-point clinical status scale will be assessed by phone interview.

Up to 376 randomized patients (full sample size) will be included in the study according to preliminary estimation.

02

Conditions studied

  • COVID-19

Keywords

  • SARS-CoV-2
  • Severe acute respiratory syndrome coronavirus 2
  • 2019-nCoV
  • 2019 novel coronavirus
  • Respiratory disease
  • lung disease
  • COVID-19
  • coronavirus
03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COVID-19 diagnosis (confirmation of the presence of SARS-CoV-2 virus by rt-PCR) OR sample collection for SARS-CoV-2 virus rt-PCR if the results of SARS-CoV-2 virus rt-PCR are not available yet.
  • Dated for participation in this study signed by the patient, or by the legally acceptable representative or when prior consent of the patient is not possible, and the subject's legally acceptable representative is not available, documented approval / favorable opinion by the IRB/IEC.
  • SpO2 ≤93% (room air) or respiratory rate greater than 30/min (room air) or oxygenation index PaO2/FiO2 ≤300 mmHg (or SpO2/FiO2 ≤315 in the case PaO2/FiO2 assessment is not available (supplementary oxygen)
  • Computed tomography findings: features consistent with bilateral COVID-19 viral pneumonia and no alternative explanation for these findings.

Exclusion criteria

Exclusion Criteria:

  • Presence of any of the following laboratory abnormalities:

\<0,5 х 10\^9/L white blood cell count \< 2 х 10\^9/L, count \< 50 х 10\^9/L, (АLT) and/or Aspartate aminotransferase (AST) ≥3,0 х (ULN)

  • Kidney injury with \<30 mL/min.
  • to OKZ, and/or its components.
  • Septic shock (need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg and lactate ≥2 mmol / L in the absence of hypovolemia).
  • Estimated survival of less than 24 hours regardless of treatment.
  • History of perforation of the gastrointestinal tract, history of diverticulitis.
  • Recent (less than 5 half-lives), current or planned during the current study period use of drugs:
  • biologics (except OKZ) with immunosuppressive effect, including, but not limited to: Interleukin-1 (IL-1) inhibitors (anakinra, rilonacept, canakinumab), IL-6 inhibitors (tocilizumab, sarilumab, siltuximab, etc.), IL-17A inhibitors (seсukinumab, etc.), Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors (infliximab, adalimumab, etanercept, etc.), anti-B-cells therapy, etc.;.
  • other immunosuppressive drugs (excluding methotrexate in dose up to 25 mg/week), including but not limited to:

    1. in high doses (> 1 mg / kg equivalent of methylprednisolone) orally and parenterally;
    2. JAK inhibitors; etc.
  • Concurrent participation in another clinical trial during 30 days before screening.
  • Pregnancy or lactation.
  • A history of active tuberculosis, or active tuberculosis suspected by the Investigator.
  • Administration of plasma from COVID-19 reconvalescent donors for 4 weeks prior to the patient's inclusion in the study and/or planned administration during the study
  • Patients who deteriorated into Category 4 of the 5-point clinical status scale within more than the last 24 hours.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Olokizumab 64 mg

    Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy

    Drug: Olokizumab 64 mg

  • Placebo comparator
    Placebo

    Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy

    Drug: Placebo

Interventions

  • solution for subcutaneous administration 160 mg/mL

  • DrugPlacebo

    Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package

06

What researchers measure

Primary outcomes

  1. Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category

    Difference between OKZ and placebo groups in the percentage of subjects with an improvement of at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category. The points of the scale are: 1. Not hospitalized; 2.Hospitalized, not requiring supplemental oxygen; 3.Hospitalized, supplemental oxygen, spontaneous breathing;4. Hospitalized, mechanical ventilation (invasive/non-invasive) or extracorporeal membrane oxygenation (ECMO); 5. Death

    Time frame: at Day 29

Secondary outcomes

  1. Subjects' clinical status distribution based on 5-point clinical status scale during the study

    Subjects' clinical status distribution based on 5-point clinical status scale during the study

    Time frame: from Day 2 tо Day 15, Day 29, Day 60

  2. 28-day case fatality rates

    28-day case fatality rates

    Time frame: from Day 1 to Day 29

Other outcomes

  1. Case fatality rates during the intensive care unit (ICU) stay, at Days 7, 15, and 60

    Case fatality rates during the intensive care unit (ICU) stay at Days 7, 15, and 60

    Time frame: from Day 1 to Day 60

  2. Duration of oxygen support

    Duration of oxygen support (if applicable)

    Time frame: From Day 1 to Day 60

  3. The time period until SpO2 ≥ 94% at ambient air during 2 consequence days is reached

    The time period until SpO2 ≥ 94% at ambient air during 2 consequence days is reached

    Time frame: from Day 2 to Day 60

  4. Changes of oxygenation index PaO2/FiO2 from baseline

    Changes of oxygenation index PaO2/FiO2 from baseline (if applicable)

    Time frame: from Day 2 to Day 60

  5. Duration of oxygen support (if applicable)

    Duration of oxygen support (if applicable), in days

    Time frame: from Day 1 to Day 60

  6. Duration of mechanical ventilation and/or ECMO (if applicable)

    Duration of mechanical ventilation and/or ECMO (if applicable), in days

    Time frame: from Day 1 to Day 60

  7. Duration of ICU stay (if applicable)

    Duration of ICU stay (if applicable)

    Time frame: from Day 1 to Day 60

  8. Changes from baseline of COVID-19 cytokine storm surrogate marker: white blood count

    Changes from baseline of COVID-19 cytokine storm surrogate marker: white blood count

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  9. Changes from baseline of COVID-19 cytokine storm surrogate marker: lymphocyte count

    Changes from baseline of COVID-19 cytokine storm surrogate marker: lymphocyte counts

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  10. Changes from baseline of COVID-19 cytokine storm surrogate marker: neutrophils count

    Changes from baseline of COVID-19 cytokine storm surrogate marker: neutrophils count

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  11. Changes from baseline of COVID-19 cytokine storm surrogate marker: C-reactive protein (CRP)

    Changes from baseline of COVID-19 cytokine storm surrogate marker: C-reactive protein (CRP)

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  12. Changes from baseline of COVID-19 cytokine storm surrogate marker: ferritin

    Changes from baseline of COVID-19 cytokine storm surrogate marker: ferritin

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  13. Changes from baseline of COVID-19 cytokine storm surrogate marker:D-dimer

    Changes from baseline of COVID-19 cytokine storm surrogate marker:D-dimer

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  14. Changes from baseline of COVID-19 cytokine storm surrogate marker:platelets

    Changes from baseline of COVID-19 cytokine storm surrogate marker:platelets

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  15. Changes from baseline of COVID-19 cytokine storm surrogate marker: triglycerides

    Changes from baseline of COVID-19 cytokine storm surrogate marker: triglycerides

    Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum

  16. The time period until National Early Warning Score 2 (NEWS2) ≤ 2 during 2 consequent days is reached

    The time period until National Early Warning Score 2 (NEWS2) ≤ 2 during 2 consequent days is reached

    Time frame: from Day 1 and until the end of hospitalization, Day 29 as a maximum

  17. The time period until National Early Warning Score 2 (NEWS2) ≤ 4 during 2 consequent days is reached

    The time period until National Early Warning Score 2 (NEWS2) ≤ 4 during 2 consequent days is reached

    Time frame: from Day 1 and until the end of hospitalization, Day 29 as a maximum

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2020; primary completion for Nov 2020, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2020
First posted
Jun 30, 2020
StartEst.
Jun 30, 2020
Primary completionEst.
Nov 16, 2020
CompletionEst.
Jan 29, 2021
Last update
Nov 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04452474
Lead sponsor
R-Pharm
Collaborators
Cromos Pharma LLC, Covance
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jun 30, 2020 (estimated)
Primary completion
Nov 16, 2020 (estimated)
Completion
Jan 29, 2021 (estimated)
Last update
Nov 8, 2021

Study contacts

Mikhail Samsonov
study director · Chief Medical Officer, R-Pharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion